Yale researchers may have found a treatment target for a spectrum of genetic disorders that lead to brain malformations, seizures, and intellectual disability.
The Louvi Laboratory
Mechanisms of Brain Morphogenesis and Pathogenesis
Our laboratory is interested in understanding the molecular mechanisms governing the development of the mammalian brain and how the perturbation of basic biological processes leads to clinically significant brain pathologies. Working closely with other research groups within the Yale Program on Neurogenetics, we study the cellular and molecular mechanisms underlying neurovascular and structural brain disorders associated with specific genetic lesions, aiming to gain insight into fundamental neurodevelopmental processes and to obtain information relevant for the design of rational therapeutic approaches.
About Angeliki Louvi
Angeliki Louvi is a Professor at Yale School of Medicine, Deputy Director of the MD-PhD Program, and a member of the Yale Program on Neurogenetics and the Interdepartmental Neuroscience Program. She obtained her PhD from the Department of Genetics and Development at Columbia University Irving Medical Center and did post-doctoral work at the École normale supérieure and at the University of Chicago. She came to Yale in 2004.
A combination of existing drugs can ease symptoms of a cerebrovascular disorder that in severe cases can lead to brain hemorrhage, a team of Yale researchers have found.